Improved survival with higher radiation dose for esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy

被引:11
作者
Deng, Yuxia [1 ]
Bian, Chao [2 ]
Tao, Hua [3 ]
Zhang, Haijun [1 ]
机构
[1] Southeast Univ, Dept Oncol, Zhongda Hosp, Med Sch, Nanjing, Jiangsu, Peoples R China
[2] Ningxia Med Univ, Ningxia, Peoples R China
[3] Jiangsu Canc Inst & Hosp, Dept Radiat Oncol, Nanjing, Jiangsu, Peoples R China
关键词
esophageal squamous cell carcinoma; radiotherapy; overall survival; progression-free survival; INVOLVED-FIELD RADIOTHERAPY; ELECTIVE NODAL IRRADIATION; CONCURRENT CHEMOTHERAPY; PREOPERATIVE CHEMORADIOTHERAPY; CANCER; PATTERNS; THERAPY; CHEMORADIATION; SURGERY; TRIAL;
D O I
10.18632/oncotarget.19030
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The optimal radiation dose for patients with esophageal squamous cell carcinoma (ESCC) has long been debated. We undertook the retrospective study to evaluate the survival impact of high dose vs standard dose in patients with stage II-III esophageal cancer treated with definitive chemoradiotherapy (CRT). Results: A total of 137 patients were included in our study, 63 patients classified as standard-dose group and 74 as high-dose group. For the 63 patients in the standard-dose group, the median PFS and the 1-, 2-, and 3-year PFS rates were 12.6 months, 58.0%, 26.0% and 12.0%, respectively; for the 74 patients in the high-dose group, they were 20.0 months, 80.1%, 31.0% and 20.0%, respectively (P = 0.013). The median OS of the patients in the standard-dose group and high-dose group groups were 19.0 months and 26.6 months, respectively, and the 1-, 2- and 3-year survival rates were 78.0%, 39.0%, and 24.0%, and 89.0%, 61.0%, and 30.0%, respectively (P = 0.037). Besides the rate of grade 3 acute irradiation esophagitis in the high dose group (10.5% versus. 2.2%, P < 0.01), there were no significantly differ of treatment-related toxicities between the two groups. Materials and Methods: According to the radiation dose, patients from 2010 to 2014 were allocated into either the standard-dose group (50-50.4 Gy) or the high dose group (>= 59.4 Gy). Overall survival (OS), progression-free survival (PFS) and treatment-related toxicities were assessed and compared between the two groups. Conclusions: Our findings suggest that higher radiation dose could perform better outcomes for esophageal squamous cell carcinoma patients.
引用
收藏
页码:79662 / 79669
页数:8
相关论文
共 28 条
[1]  
[Anonymous], CANC RES TREAT
[2]  
Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118
[3]   STUDY TO DETERMINE ADEQUATE MARGINS IN RADIOTHERAPY PLANNING FOR ESOPHAGEAL CARCINOMA BY DETAILING PATTERNS OF RECURRENCE AFTER DEFINITIVE CHEMORADIOTHERAPY [J].
Button, Michael R. ;
Morgan, Carys A. ;
Croydon, Elizabeth S. ;
Roberts, S. Ashley ;
Crosby, Thomas D. L. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03) :818-823
[4]   Chemoradiotherapy of locally advanced esophageal cancer - Long-term follow-up of a prospective randomized trial (RTOG 85-01) [J].
Cooper, JS ;
Guo, MD ;
Herskovic, A ;
Macdonald, JS ;
Martenson, JA ;
Al-Sarraf, M ;
Byhardt, R ;
Russell, AH ;
Beitler, JJ ;
Spencer, S ;
Asbell, SO ;
Graham, MV ;
Leichman, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17) :1623-1627
[5]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[6]   Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 [J].
Ferlay, Jacques ;
Shin, Hai-Rim ;
Bray, Freddie ;
Forman, David ;
Mathers, Colin ;
Parkin, Donald Maxwell .
INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (12) :2893-2917
[7]  
Gaspar LE, 2000, CANCER, V88, P988, DOI 10.1002/(SICI)1097-0142(20000301)88:5<988::AID-CNCR7>3.0.CO
[8]  
2-U
[9]   Re-evaluating the Optimal Radiation Dose for Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma [J].
He, Liru ;
Allen, Pamela K. ;
Potter, Adam ;
Wang, Jingya ;
Chang, Joe Y. ;
Gomez, Daniel R. ;
Komaki, Ritsuko ;
Liao, Zhongxing ;
Lin, Steven H. .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) :1398-1405
[10]   COMBINED CHEMOTHERAPY AND RADIOTHERAPY COMPARED WITH RADIOTHERAPY ALONE IN PATIENTS WITH CANCER OF THE ESOPHAGUS [J].
HERSKOVIC, A ;
MARTZ, K ;
ALSARRAF, M ;
LEICHMAN, L ;
BRINDLE, J ;
VAITKEVICIUS, V ;
COOPER, J ;
BYHARDT, R ;
DAVIS, L ;
EMAMI, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (24) :1593-1598